ALX Oncology Highlights Focused Evorpacept Development Plan, Clinical Progress and Corporate Updates at R&D Day Webcast Event

Core Insights - ALX Oncology is advancing its clinical pipeline, focusing on the CD47-blocker evorpacept and the novel EGFR-directed ADC candidate ALX2004, with key updates provided during an R&D Day webcast event [1][8] Clinical Development Updates - The company is optimistic about evorpacept's potential, particularly for HER2-positive cancers, and plans to initiate new clinical trials combining evorpacept with trastuzumab and cetuximab in breast and colorectal cancers in the first half of 2025 [3][4] - Evorpacept is currently being evaluated in ongoing trials, with discussions on regulatory pathways for gastric cancer based on ASPEN-06 data [3][4] New Product Introduction - ALX2004, a new ADC candidate, is designed to enhance anti-tumor activity and is expected to have an IND application submitted to the FDA in Q1 2025 [6][8] Corporate Strategy and Financial Updates - The company is streamlining operations and prioritizing resources, resulting in a workforce reduction of approximately 30% in preclinical research to extend its cash runway into Q4 2026 [3][9] - The strategic prioritization aims to support new clinical trial programs while optimizing existing resources [9]